C2N Diagnostics has secured coverage for its PrecivityAD2 blood test under a revised Anthem medical policy, giving eligible Anthem Blue Cross and Blue Shield members an insurance pathway for blood-based Alzheimer’s disease evaluation beginning October 1, 2026. The test is intended for adults aged 50 and older who have signs or symptoms of cognitive impairment and are being evaluated for Alzheimer’s disease or another cause of cognitive decline.
The decision represents a substantial commercial milestone for the privately held diagnostics company because reimbursement, rather than analytical performance alone, has become one of the main barriers separating Alzheimer’s blood biomarkers from routine clinical use. PrecivityAD2 has accumulated clinical validation data and growing specialist awareness, but patients have frequently faced uncertain insurance coverage or direct payment requirements.
Anthem Blue Cross and Blue Shield plans are offered through affiliates of Elevance Health across 14 states, giving the policy the potential to influence a sizeable insured population. However, the October coverage change should not be interpreted as unrestricted access or a population-wide Alzheimer’s screening programme. Anthem has established detailed medical necessity requirements that will determine which patients, physicians and clinical situations qualify.
Why does Anthem coverage represent more than a routine diagnostic policy update?
The importance of the Anthem decision lies in its recognition of blood-based biomarkers as a reimbursable part of the diagnostic pathway, rather than merely an emerging research technology. Private insurers have historically been cautious about tests that identify biological features of Alzheimer’s disease because evidence of analytical accuracy does not automatically establish that a test improves patient management or reduces healthcare spending.
C2N Diagnostics has therefore crossed an important boundary. PrecivityAD2 is moving from a commercially available laboratory-developed test with peer-reviewed validation into a diagnostic product recognised within the formal coverage rules of one of the largest United States health plan networks.
That recognition could improve physician confidence in ordering the test, particularly when patients cannot easily access an amyloid positron emission tomography scan or undergo cerebrospinal fluid testing. It may also lower the financial uncertainty faced by patients who previously did not know whether the cost would be reimbursed.
Coverage does not guarantee payment in every case. Individual benefit designs, deductibles, coinsurance, network requirements, claim documentation and medical necessity reviews can still affect reimbursement. The true commercial impact will depend on how consistently Anthem-affiliated plans implement the policy and how easily clinicians can demonstrate that their patients meet the required criteria.
Which patients are most likely to qualify for PrecivityAD2 testing under Anthem’s policy?
Anthem’s policy is directed at people with clinically measurable cognitive impairment, not healthy individuals seeking reassurance because of age, family history or general concern about future dementia risk. Eligible patients must have mild cognitive impairment or dementia associated with an insidious onset and progressive decline.
The diagnosis must also remain uncertain after a conventional evaluation. That process may include a medical history, neurological examination, cognitive assessment, appropriate imaging and investigations for potentially reversible causes such as thyroid dysfunction, vitamin B12 deficiency, depression or medication-related effects.
The biomarker result must be expected to influence management. Potential uses include differentiating Alzheimer’s disease from other forms of dementia, evaluating an atypical or early-onset presentation, resolving inconsistencies between clinical findings and imaging, improving diagnostic confidence or helping determine whether a disease-targeting treatment should be considered.
For blood-based testing, Anthem requires patients to be at least 50 years old. The assay must either have regulatory clearance or approval, or measure p-tau217 or percentage p-tau217. PrecivityAD2 meets the biomarker pathway because it incorporates percentage p-tau217 into its calculation.
This detail is commercially significant. PrecivityAD2 is offered as a laboratory-developed test rather than as an independently marketed, FDA-cleared in vitro diagnostic kit. Anthem’s decision to recognise qualifying p-tau217 tests therefore creates a route to coverage that does not depend exclusively on product-specific FDA clearance.
At the same time, the documentation burden may limit uptake. Physicians will need to show that cognitive impairment has been objectively evaluated, common alternative explanations have been considered and the test result will affect a clinical decision. Practices without established dementia assessment workflows may find those requirements more demanding than specialist memory clinics.
How does PrecivityAD2 compare with amyloid PET scans and cerebrospinal fluid testing?
PrecivityAD2 uses a blood sample to measure the amyloid beta 42 to amyloid beta 40 ratio and the proportion of tau phosphorylated at threonine 217. These biomarker measurements are combined through a proprietary algorithm to produce the Amyloid Probability Score 2, or APS2, on a scale from zero to 100.
The score estimates the likelihood that amyloid plaques are present in the brain. Amyloid accumulation is a defining pathological feature associated with Alzheimer’s disease, although the presence of amyloid does not by itself explain every patient’s cognitive symptoms or establish the complete clinical diagnosis.
Clinical studies have shown that the APS2 approach can achieve approximately 90% or higher accuracy in selected symptomatic populations when compared with amyloid PET imaging or cerebrospinal fluid reference testing. An independent validation involving cognitively impaired participants also reported sensitivity and specificity around the 90% level.
These results make PrecivityAD2 a credible alternative or triage tool, but they do not make it infallible. Predictive value changes with the prevalence of amyloid pathology in the tested population. A positive result is more dependable when clinical suspicion is already high, while testing people with a low probability of Alzheimer’s disease increases the risk that a positive result will not reflect the primary cause of their symptoms.
PrecivityAD2 is also not intended to operate as a standalone diagnosis. Clinicians must interpret the score alongside the patient’s cognitive history, examination, imaging, laboratory findings and other medical information. Some patients may still require PET imaging or cerebrospinal fluid analysis, particularly when results conflict with the clinical presentation or when treatment protocols demand additional confirmation.
Operational factors will matter as adoption expands. The test uses liquid chromatography and tandem mass spectrometry and is processed through a specialist laboratory workflow. Blood collection is less invasive than lumbar puncture and generally more accessible than PET imaging, but specimen preparation, shipping, laboratory capacity and result turnaround remain part of the service model.
Could insured blood testing shorten the path to disease-modifying Alzheimer’s treatment?
The arrival of amyloid-targeting therapies has increased the clinical value of determining whether a patient’s cognitive impairment is associated with Alzheimer’s pathology. Treatment decisions require more than a general dementia diagnosis because clinicians must identify patients at an appropriate disease stage and establish evidence of amyloid before considering therapy.
A covered blood test could be used earlier in the diagnostic sequence to identify patients with a low likelihood of amyloid pathology and redirect their evaluation toward other neurological, psychiatric or medical causes. It could also identify patients with a high probability of amyloid who should progress to specialist assessment, additional imaging or treatment evaluation.
This triage role may be particularly valuable in communities with limited access to memory specialists and amyloid PET facilities. A standard blood draw can be performed across a much wider healthcare network than advanced neurological imaging, potentially reducing geographic and logistical barriers.
The efficiency benefits should not be overstated. A blood result does not determine whether a patient is clinically suitable for an anti-amyloid medicine. Treatment assessment may also require magnetic resonance imaging, genetic or bleeding-risk evaluation, discussion of potential adverse events and the ability to complete repeated monitoring.
There is also a risk that expanded testing could increase specialist referrals faster than neurology services can absorb them. A more accessible front-end diagnostic tool may expose an existing shortage of memory-care capacity rather than solve it. Health systems will need clear referral rules so that testing creates a more efficient pathway instead of another queue.
How could Anthem’s policy affect competing Alzheimer’s blood biomarker platforms?
The Alzheimer’s blood testing market is developing through several technological and regulatory models. Fujirebio Diagnostics received FDA clearance for the Lumipulse G pTau217 to beta-amyloid 1-42 Plasma Ratio, while Roche Diagnostics has secured clearance for its Elecsys Phospho-Tau 181P Plasma assay.
Those products are designed for use on established laboratory analyser platforms. PrecivityAD2 follows a central laboratory model using mass spectrometry and a multi-analyte algorithm. The differences could influence turnaround time, scalability, laboratory adoption, pricing and how payers compare clinical performance.
Anthem’s policy is notable because it is not limited to a single named commercial assay. The criteria recognise qualifying blood tests that have regulatory clearance or that measure p-tau217 or percentage p-tau217. That approach could support broader category adoption while allowing competition among different diagnostic technologies.
C2N Diagnostics nevertheless gains a valuable first-mover advantage from being publicly associated with the policy change. Payer recognition can strengthen relationships with memory clinics, neurologists, healthcare systems and laboratory partners. It may also provide real-world utilisation data that support negotiations with additional insurers.
Competition is likely to intensify as large diagnostics manufacturers use their installed laboratory bases to bring Alzheimer’s biomarker testing closer to routine chemistry and immunoassay workflows. C2N Diagnostics will need to demonstrate that the combined APS2 algorithm offers enough clinical value to justify its specialised processing model.
Why does reimbursement remain the most important commercial test for C2N Diagnostics?
Clinical validation establishes whether a test performs reliably under defined conditions. Reimbursement determines whether the product can reach a meaningful number of patients without relying heavily on direct payment.
Anthem coverage therefore expands C2N Diagnostics’ commercial opportunity, but it does not reveal how many claims will be submitted, what reimbursement level will apply or how many patients will satisfy the policy. The company has not disclosed the financial terms associated with the coverage decision.
Utilisation will depend partly on physician awareness. Many primary care practices are still developing confidence in Alzheimer’s biomarkers and may be uncertain about which test to order, how to interpret the result and when to refer a patient for further evaluation.
Claim acceptance will be another crucial indicator. A policy can recognise a service as medically necessary while actual reimbursement remains inconsistent because of coding errors, incomplete clinical notes, benefit exclusions or differences between fully insured and employer-funded health plans.
C2N Diagnostics will also need broader payer replication. One major insurer can establish momentum, but nationwide commercial scale requires coverage across additional private plans and a more predictable pathway for Medicare beneficiaries, who represent a large share of the population undergoing dementia evaluation.
The company’s next commercial challenge is therefore to convert a policy victory into measurable test volumes, reliable payment and repeat ordering behaviour. Evidence that PrecivityAD2 reduces unnecessary imaging, improves referral decisions or shortens the diagnostic process would strengthen the economic argument for wider coverage.
What does the decision mean for Elevance Health and investor sentiment?
Anthem Blue Cross and Blue Shield plans form an important part of Elevance Health’s health benefits portfolio. The coverage decision signals that the insurer is becoming more receptive to clinically validated blood biomarkers when testing is tied to documented symptoms and a defined management decision.
For Elevance Health, the policy creates both potential savings and utilisation risks. Blood testing may reduce some dependence on expensive amyloid PET imaging or invasive cerebrospinal fluid procedures. Conversely, easier access could increase the number of people entering Alzheimer’s diagnostic and treatment pathways, creating additional spending on specialist consultations, imaging, medicines and monitoring.
Elevance Health shares closed at $416.23 on July 10, 2026. The stock had gained about 2% over the preceding five trading days and approximately 3.6% over one month, while trading within roughly 3% of its 52-week high.
That market performance reflects broader investor expectations surrounding Elevance Health rather than the PrecivityAD2 policy alone. The coverage decision is unlikely to be a material near-term earnings catalyst for a company of Elevance Health’s scale. Its significance lies more in how the insurer is managing the transition from conventional symptom-based dementia assessment toward biomarker-supported care.
Investors may eventually focus on whether earlier and more accurate diagnostic triage can lower avoidable spending. The financial outcome will depend on whether reduced use of more expensive procedures outweighs higher testing volumes and increased access to costly disease-modifying treatments.
What should clinicians, payers and diagnostics companies watch before October 2026?
The months before implementation should provide greater clarity on benefit administration, coding, documentation expectations and whether prior authorisation will be required. Provider communications will be important because a policy has limited practical value when clinicians do not understand how to order the test or establish medical necessity.
Patient cost sharing will also influence utilisation. Insurance coverage can reduce financial barriers without eliminating them, particularly for members with high deductibles or coinsurance. Differences among employer plans and state-specific products may produce uneven access across Anthem’s network.
The diagnostics industry will closely watch whether other commercial insurers introduce similar policies. A series of payer decisions would indicate that Alzheimer’s blood biomarkers are entering a more mature reimbursement phase. A lack of follow-through would suggest that Anthem is an early exception rather than the beginning of a wider shift.
C2N Diagnostics must now show that covered access produces consistent clinical adoption. The strongest evidence will come from real-world ordering patterns, claim approval rates, changes in the use of PET and cerebrospinal fluid testing, and documented effects on treatment or referral decisions.
Anthem’s decision removes one of the most visible commercial obstacles facing PrecivityAD2, but it does not remove the need for careful patient selection, clinical interpretation and evidence of healthcare value. The October rollout will test whether an Alzheimer’s blood biomarker can move beyond scientific validation and become a dependable part of insured clinical practice.
